Ruxolitinib cream 1.5% twice daily for the treatment of extensive atopic dermatitis in children aged 2-11 years: 52 week results from a maximum-use trial

被引：0
|
作者：
Bissonnette, Robert [1 ]
Lee, Mark S. [2 ]
Forman, Seth B. [3 ]
Gold, Linda Stein [4 ]
Kallender, Howard [5 ]
Angel, Brett [5 ]
Kuo, Yutzu [5 ]
Paller, Amy S. [6 ]
机构：
[1] Innovaderm Res, Montreal, PQ, Canada
[2] Progress Clin Res, San Antonio, TX USA
[3] ForCare Clin Res, Tampa, FL USA
[4] Henry Ford Hlth Syst, Detroit, MI USA
[5] Incyte Corp, Wilmington, DE USA
[6] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 191卷
关键词：
atopic dermatitis; pediatric; ruxolitinib cream;
D O I：
10.1093/bjd/ljae266.003
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
603
引用
收藏
页数：1
相关论文
共 13 条
  • [1] A Maximum-Use Trial of Ruxolitinib Cream in Children Aged 2-11 Years with Moderate to Severe Atopic Dermatitis
    Stein Gold, Linda
    Bissonnette, Robert
    Forman, Seth
    Zaenglein, Andrea
    Kuo, Yutzu
    Angel, Brett
    Chen, Xuejun
    Kallender, Howard
    Paller, Amy S.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2025, 26 (02) : 275 - 289
  • [2] Tapinarof cream 1% once daily for the treatment of extensive atopic dermatitis in adolescents and children: 4-week maximal use trial
    Paller, Amy
    Hebert, Adelaide A.
    Jett, John E.
    Brown, Philip M.
    Rubenstein, David S.
    Piscitelli, Stephen C.
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [3] Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with moderate and/or more extensive atopic dermatitis: subgroup analysis from the TRuE-AD3 study
    Eichenfield, Lawrence F.
    Armstrong, April W.
    Gold, Linda F. Stein
    Zaenglein, Andrea L.
    Lee, Lara Wine
    Brar, Kanwaljit K.
    Joyce, Joel C.
    Holland, Kristen E.
    Angel, Brett
    Sturm, Daniel
    Li, Qian
    Simpson, Eric L.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [4] Tapinarof cream 1% once daily for the treatment of extensive atopic dermatitis in adolescents and children: outcomes from the 4-week maximal usage trial
    Paller, Amy
    Jett, John E.
    Hebert, Adelaide
    Brown, Philip M.
    Butners, Victoria
    Fitzgerald, Nancy
    Delgado, Marta
    Gonzalez, Mercedes E.
    Piscitelli, Stephen C.
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [5] A 52-week multicenter retrospective real-world study on effectiveness and safety of dupilumab in children with atopic dermatitis aged from 6 to 11 years
    Patruno, Cataldo
    Fabbrocini, Gabriella
    Lauletta, Giuseppe
    Boccaletti, Valeria
    Colonna, Cristiana
    Cavalli, Riccardo
    Neri, Iria
    Ortoncelli, Michela
    Schena, Donatella
    Stingeni, Luca
    Hansel, Katharina
    Piccolo, Vincenzo
    Di Brizzi, Veronica
    Potenza, Concetta
    Tolino, Ersilia
    Bianchi, Luca
    Manti, Sara
    De Pasquale, Rocco
    Di Lernia, Vito
    Caminiti, Lucia
    Galli, Elena
    Coppo, Paola
    Chiricozzi, Andrea
    De Simone, Clara
    Guerriero, Cristina
    Amoruso, Fabrizio Giuseppe
    Provenzano, Eugenio
    Leonardi, Salvatore
    Licari, Amelia
    Marseglia, Gian Luigi
    Palermo, Antonino
    Di Pillo, Sabrina
    Russo, Daniele
    Moschese, Viviana
    Patella, Vincenzo
    Peduto, Tiziana
    Ferreli, Caterina
    Zangari, Paola
    Veronese, Federica
    Berti, Samantha Federica
    Gruber, Michaela
    Pezzolo, Elena
    Termine, Stefania
    Satta, Rosanna
    Dragoni, Federica
    Esposito, Maria
    Fargnoli, Maria Concetta
    Chiodini, Paolo
    Vallone, Ylenia
    di Vico, Francesca
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2023, 34 (01)
  • [6] Efficacy and Safety of Ruxolitinib Cream Among Children With Atopic Dermatitis Aged 2 to 6 Years and 7 to <12 Years: Results from a Phase 3 Double-Blind Vehicle-Controlled Study
    Soong, Weily
    Zaenglein, Andrea
    Tollefson, Megha
    Simpson, Eric
    Devani, Alim
    Joyce, Joel
    Forsha, Douglass
    Schlessinger, Joel
    Kallender, Howard
    Angel, Brett
    Li, Qian
    Paller, Amy
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB1 - AB1
  • [7] Dupilumab significantly improves atopic dermatitis in children aged 6-11 years: results from a phase III trial (LIBERTY AD PEDS)
    Paller, A. S.
    Siegfried, E. C.
    Gooderham, M.
    Beck, L. A.
    Boguniewicz, M.
    Sher, L.
    Weisman, J.
    Staudinger, H. W.
    Sun, X.
    Shumel, B.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (04) : E121 - E121
  • [8] Long-term safety and efficacy of roflumilast cream 0.15% in adults and children aged ≥6 years with mild to moderate atopic dermatitis: a 52-week, phase 3, open-label extension trial
    Simpson, Eric L.
    Eichenfield, Lawrence F.
    Papp, Kim A.
    Forman, Seth
    Hebert, Adelaide A.
    Gonzalez, Mercedes E.
    Gooderham, Melinda
    Hong, H. Chih-ho
    Prajapati, Vimal H.
    Guttman, Emma
    Silverberg, Jonathan
    Seal, Melissa
    Krupa, David
    Burnett, Patrick
    Synder, Scott
    Chu, David H.
    Higham, Robert C.
    Berk, David R.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : 20 - 20
  • [9] Dupilumab Provides Clinically Meaningful Responses in Children Aged 6–11 Years with Severe Atopic Dermatitis: Post Hoc Analysis Results from a Phase III Trial
    Elaine C. Siegfried
    Michael J. Cork
    Norito Katoh
    Haixin Zhang
    Chien-Chia Chuang
    Ryan B. Thomas
    Ana B. Rossi
    Sonya L. Cyr
    Annie Zhang
    American Journal of Clinical Dermatology, 2023, 24 : 787 - 798
  • [10] Dupilumab Provides Clinically Meaningful Responses in Children Aged 6-11 Years with Severe Atopic Dermatitis: Post Hoc Analysis Results from a Phase III Trial
    Siegfried, Elaine C.
    Cork, Michael J.
    Katoh, Norito
    Zhang, Haixin
    Chuang, Chien-Chia
    Thomas, Ryan B.
    Rossi, Ana B.
    Cyr, Sonya L.
    Zhang, Annie
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2023, 24 (05) : 787 - 798
12